# Blood Pressure Control of Nifedipine GITS 60mg Treatment in Chinese Hypertensive Subjects Uncontrolled on Starting-dose Mono-therapyo-therapy.

Study · id `cardio:ct-nct02413515` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02413515](<https://clinicaltrials.gov/study/NCT02413515>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02413515

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 278 participants.

## Technical summary

Registry record NCT02413515. Allocation not applicable; no masking; primary purpose treatment. Start 2015-03-26 (actual); primary completion 2016-08-08 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 278 participants (enrolled count; ClinicalTrials.gov record NCT02413515, source copy `cardio:ctgov-nct02413515-2017-08-04`, retrieved 2026-10-26)
- Started: 2015-03-26 (actual) (ClinicalTrials.gov record NCT02413515, source copy `cardio:ctgov-nct02413515-2017-08-04`, retrieved 2026-10-26)
- Primary completion: 2016-08-08 (actual) (ClinicalTrials.gov record NCT02413515, source copy `cardio:ctgov-nct02413515-2017-08-04`, retrieved 2026-10-26)
- Completion: 2016-08-08 (actual) (ClinicalTrials.gov record NCT02413515, source copy `cardio:ctgov-nct02413515-2017-08-04`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT02413515, source copy `cardio:ctgov-nct02413515-2017-08-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02413515-2017-08-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: Blood Pressure Control of Nifedipine GITS 60mg Treatment in Chinese Hypertensive Subjects Uncontrolled on Starting-dose Mono-therapyo-therapy.
- Acronym: ADEPT
- Condition: Hypertension
- Intervention (Drug): Nifedipine (Adalat GITS, BAY1040)
- Lead sponsor: Bayer
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Nifedipine (`cardio:nifedipine`)
- Registry intervention is a member of this class by a sourced record link: Calcium channel blockers (`cardio:calcium-channel-blockers`)
- Registry lists this organization as the lead sponsor: Bayer (`cardio:bayer`)

## Provenance

Content hash: b8d08534f5e28b88d40a6525292c899ba77d17b47052b95834e8c3ad8b440994
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
